These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 29577455)

  • 1. Diminished impact of cytomegalovirus infection on graft vasculopathy development in the antiviral prophylaxis era - a retrospective study.
    Goekler J; Zuckermann A; Kaider A; Angleitner P; Osorio-Jaramillo E; Moayedifar R; Uyanik-Uenal K; Kainz FM; Masetti M; Laufer G; Aliabadi-Zuckermann AZ
    Transpl Int; 2018 Aug; 31(8):909-916. PubMed ID: 29577455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of cytomegalovirus infection in the development of cardiac allograft vasculopathy after heart transplantation.
    Delgado JF; Reyne AG; de Dios S; López-Medrano F; Jurado A; Juan RS; Ruiz-Cano MJ; Dolores Folgueira M; Gómez-Sánchez MÁ; Aguado JM; Lumbreras C
    J Heart Lung Transplant; 2015 Aug; 34(8):1112-9. PubMed ID: 25940077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytomegalovirus infection and disease reduce 10-year cardiac allograft vasculopathy-free survival in heart transplant recipients.
    Johansson I; Andersson R; Friman V; Selimovic N; Hanzen L; Nasic S; Nyström U; Sigurdardottir V
    BMC Infect Dis; 2015 Dec; 15():582. PubMed ID: 26703239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Association Between Cytomegalovirus Infection and Cardiac Allograft Vasculopathy in the Era of Antiviral Valganciclovir Prophylaxis.
    Klimczak-Tomaniak D; Roest S; Brugts JJ; Caliskan K; Kardys I; Zijlstra F; Constantinescu AA; Voermans JJC; van Kampen JJA; Manintveld OC
    Transplantation; 2020 Jul; 104(7):1508-1518. PubMed ID: 31644496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome of cardiac allograft vasculopathy: Importance of the International Society for Heart and Lung Transplantation angiographic grading scale.
    Van Keer JM; Van Aelst LNL; Rega F; Droogne W; Voros G; Meyns B; Vanhaecke J; Emonds MP; Janssens S; Naesens M; Van Cleemput J
    J Heart Lung Transplant; 2019 Nov; 38(11):1189-1196. PubMed ID: 31543298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positive pretransplantation cytomegalovirus serology is a risk factor for cardiac allograft vasculopathy in children.
    Hussain T; Burch M; Fenton MJ; Whitmore PM; Rees P; Elliott M; Aurora P
    Circulation; 2007 Apr; 115(13):1798-805. PubMed ID: 17353448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does cytomegalovirus serology impact outcome after pediatric heart transplantation?
    Mahle WT; Fourshee MT; Naftel DM; Alejos JC; Caldwell RL; Uzark K; Berg A; Kanter KR;
    J Heart Lung Transplant; 2009 Dec; 28(12):1299-305. PubMed ID: 19783178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in Outcomes of Cardiac Allograft Vasculopathy Over 30 Years Following Heart Transplantation.
    Tremblay-Gravel M; Racine N; de Denus S; Ducharme A; Pelletier GB; Giraldeau G; Liszkowski M; Parent MC; Carrier M; Fortier A; White M
    JACC Heart Fail; 2017 Dec; 5(12):891-901. PubMed ID: 29191295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of late-onset cytomegalovirus infection in the development of cardiac allograft vasculopathy in heart transplant recipients.
    Ponz de Antonio I; Rodríguez Chaverri A; García Reyne A; Carrasco Antón N; Lora Pablos D; López Medrano F; de Dios S; Jurado A; Folgueira MD; García-Cosio Carmena MD; Arribas Ynsaurriaga F; Aguado JM; Lumbreras C; Delgado Jiménez JF
    Transpl Infect Dis; 2021 Apr; 23(2):e13479. PubMed ID: 32996216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of cytomegalovirus infection, confirmed by pp65 antigen presence, on the development of cardiac allograft vasculopathy.
    Zakliczyński M; Krynicka-Mazurek A; Pyka Ł; Trybunia D; Nadziakiewicz P; Przybylski R; Zembala M
    Transplant Proc; 2007 Nov; 39(9):2866-9. PubMed ID: 18022004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylaxis versus preemptive anti-cytomegalovirus approach for prevention of allograft vasculopathy in heart transplant recipients.
    Potena L; Grigioni F; Magnani G; Lazzarotto T; Musuraca AC; Ortolani P; Coccolo F; Fallani F; Russo A; Branzi A
    J Heart Lung Transplant; 2009 May; 28(5):461-7. PubMed ID: 19416774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic accuracy of coronary angiography and risk factors for post-heart-transplant cardiac allograft vasculopathy.
    Sharples LD; Jackson CH; Parameshwar J; Wallwork J; Large SR
    Transplantation; 2003 Aug; 76(4):679-82. PubMed ID: 12973108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytomegalovirus infection and allograft rejection among pediatric heart transplant recipients in the era of valganciclovir prophylaxis.
    Das BB; Prusty BK; Niu J; Sue PK
    Pediatr Transplant; 2020 Dec; 24(8):e13750. PubMed ID: 32573886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of cytomegalovirus in cardiac allograft vasculopathy.
    Weill D
    Transpl Infect Dis; 2001; 3 Suppl 2():44-8. PubMed ID: 11926750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of post-prophylaxis cytomegalovirus infection in lung transplant recipients.
    Jaamei N; Koutsokera A; Pasquier J; Mombelli M; Meylan P; Pascual M; Aubert JD; Manuel O
    Transpl Infect Dis; 2018 Aug; 20(4):e12893. PubMed ID: 29603543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Clinical Rejection Versus Rejection on Protocol Biopsy With Cardiac Allograft Vasculopathy in Pediatric Heart Transplant Recipients.
    Asimacopoulos EP; Garbern JC; Gauvreau K; Blume ED; Daly KP; Singh TP
    Transplantation; 2020 Jan; 104(1):e31-e37. PubMed ID: 31568274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytomegalovirus Donor Seropositivity Negatively Affects Survival After Heart Transplantation.
    Heim C; Müller PP; Tandler R; Cherikh WS; Toll AE; Stehlik J; Weyand M; Khush KK; Ensminger SM
    Transplantation; 2022 Jun; 106(6):1243-1252. PubMed ID: 34560698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection.
    Potena L; Holweg CT; Chin C; Luikart H; Weisshaar D; Narasimhan B; Fearon WF; Lewis DB; Cooke JP; Mocarski ES; Valantine HA
    Transplantation; 2006 Aug; 82(3):398-405. PubMed ID: 16906040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of cardiac allograft vasculopathy in heart and heart-lung transplantations: a 15-year retrospective study.
    Guihaire J; Mercier O; Flécher E; Aymami M; Fattal S; Chabanne C; Leroy Ladurie F; Lelong B; Cerrina J; Langanay T; Mussot S; Fabre D; De Latour B; Corbineau H; Verhoye JP; Dartevelle P; Leguerrier A; Fadel E
    J Heart Lung Transplant; 2014 Jun; 33(6):636-43. PubMed ID: 24630860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of Cardiac Allograft Vasculopathy by PCI: Quantification and Correlation With Outcome After Heart Transplantation.
    Orban M; Kuehl A; Pechmajou L; Müller C; Sfeir M; Brunner S; Braun D; Hausleiter J; Bories MC; Martin AC; Ulrich S; Dalla Pozza R; Mehilli J; Jouven X; Hagl C; Karam N; Massberg S
    J Card Fail; 2024 Oct; 30(10):1222-1230. PubMed ID: 39389730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.